Cargando…

Can ACEI/ARB prevent the cardiotoxicity caused by chemotherapy in early-stage breast cancer?—a meta-analysis of randomized controlled trials

BACKGROUND: Administration of anthracycline-based chemotherapy with or without trastuzumab is recognized as standard care for breast cancer, but it is associated with a decline in left ventricular ejection fraction (LVEF). Angiotensin-converting enzyme inhibitors (ACEI)/angiotensin II receptor block...

Descripción completa

Detalles Bibliográficos
Autores principales:	Dong, Haoran, Yao, Litong, Wang, Mozhi, Wang, Mengshen, Li, Xinyan, Sun, Xiangyu, Yu, Xueting, Guo, Jingyi, Li, Xiang, Xu, Yingying
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2020
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799108/ https://www.ncbi.nlm.nih.gov/pubmed/35117309 http://dx.doi.org/10.21037/tcr-20-1869

Ejemplares similares

Updated Bayesian Network Meta-Analysis of Adjuvant Targeted Treatment Regimens for Early Human Epidermal Growth Factor Receptor-2 Positive Breast Cancer
por: Li, Xinyan, et al.
Publicado: (2020)

Metabolic Reprogramming in Triple-Negative Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

Predictive and Prognostic Roles of Pathological Indicators for Patients with Breast Cancer on Neoadjuvant Chemotherapy
por: Li, Xinyan, et al.
Publicado: (2019)

Exploring the Metabolic Vulnerabilities of Epithelial–Mesenchymal Transition in Breast Cancer
por: Sun, Xiangyu, et al.
Publicado: (2020)

The choice of a neoadjuvant chemotherapy cycle for breast cancer has significance in clinical practice: results from a population-based, real world study
por: Yao, Litong, et al.
Publicado: (2022)

Role of Proton-Coupled Monocarboxylate Transporters in Cancer: From Metabolic Crosstalk to Therapeutic Potential
por: Sun, Xiangyu, et al.
Publicado: (2020)

HIF-1-induced mitochondrial ribosome protein L52: a mechanism for breast cancer cellular adaptation and metastatic initiation in response to hypoxia
por: Li, Xinyan, et al.
Publicado: (2021)

ACEI/ARB and beta-blocker therapies for preventing cardiotoxicity of antineoplastic agents in breast cancer: a systematic review and meta-analysis
por: Gao, Yu, et al.
Publicado: (2023)

ACEIs and ARBs and Their Correlation with COVID-19: A Review
por: Yehualashet, Awgichew Shewasinad, et al.
Publicado: (2020)

The role of ACEIs/ARBs in COVID-19: Friend or foe?
por: Zhou, Zhe, et al.
Publicado: (2020)

Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
Publicado: (2021)

An Immune Model to Predict Prognosis of Breast Cancer Patients Receiving Neoadjuvant Chemotherapy Based on Support Vector Machine
por: Wang, Mozhi, et al.
Publicado: (2021)

ARB might be superior to ACEI for treatment of hypertensive COVID‐19 patients
por: Zhao, Hong‐Jin, et al.
Publicado: (2021)

Effects of ACEI and ARB on COVID-19 patients: A meta-analysis
por: Xue, Yang, et al.
Publicado: (2020)

ACEI inhibitors and ARBs do not increase severity of COVID-19
Publicado: (2020)

Outcomes in Patients with COVID-19 Infection Taking ACEI/ARB
por: Rico-Mesa, Juan Simon, et al.
Publicado: (2020)

Is there a difference in the effect between the ACEI and ARB on COVID‐19?
por: Chen, Jie, et al.
Publicado: (2020)

ACEI/ARB Drug Therapy in COVID-19 Patients: Yes Or No?
por: Gong, Jin, et al.
Publicado: (2021)

Personalized prescription of ACEI/ARBs for hypertensive COVID-19 patients
por: Bertsimas, Dimitris, et al.
Publicado: (2021)

Antihypertensive treatment with ACEI/ARB of patients with COVID-19 complicated by hypertension
por: Li, Gang, et al.
Publicado: (2020)

MicroRNA Expression Profile in CAD Patients and the Impact of ACEI/ARB
por: Weber, Martina, et al.
Publicado: (2011)

Would ACEIs/ARBs be beneficial for COVID-19 patients without hypertension?
por: Huang, Ying, et al.
Publicado: (2020)

Review of evidence on using ACEi and ARBs in patients with hypertension and COVID-19
por: Khan, Sikandar Hayat, et al.
Publicado: (2020)

Safety of ACEi and ARB in COVID‐19 management: A retrospective analysis
por: Kumar, Sabina, et al.
Publicado: (2022)

Cardiovascular and cerebrovascular outcomes in elderly hypertensive patients treated with either ARB or ACEI
por: Ma, Cong, et al.
Publicado: (2012)

ARNI versus ACEI/ARB in Reducing Cardiovascular Outcomes after Myocardial Infarction
por: She, Jianqing, et al.
Publicado: (2021)

Association of ACEi/ARB Use and Clinical Outcomes of COVID-19 Patients With Hypertension
por: Ma, Jing, et al.
Publicado: (2021)

The clinical efficacy of fluticasone propionate combined with ACEI/ARB in the treatment of immunoglobulin A nephropathy
por: Sun, Liping, et al.
Publicado: (2023)

COVID-19, ACEI/ARBs, and Gastrointestinal Symptoms: The Jury Is Still Out on the Association
por: Parigi, Tommaso Lorenzo, et al.
Publicado: (2021)

ACEIs, ARBs, ibuprofen originally linked to COVID-19: the other side of the mirror
por: Kelleni, Mina T.
Publicado: (2020)

Accepting Medication Therapy Management Recommendations to Add ACEIs or ARBs in Diabetes Care
por: Hurwitz, Jason T., et al.
Publicado: (2016)

Comparing clinical outcomes of ARB and ACEi in patients hospitalized for acute COVID-19
por: Hamada, Seiji, et al.
Publicado: (2023)

Nomogram for predicting axillary lymph node status after neoadjuvant chemotherapy in breast cancer
por: Wang, Mengshen, et al.
Publicado: (2020)

Antihypertensive Therapy by ACEI/ARB Is Associated With Intestinal Flora Alterations and Metabolomic Profiles in Hypertensive Patients
por: Dong, Ying, et al.
Publicado: (2022)

ACEI and ARB Lower the Incidence of End-Stage Renal Disease among Patients with Diabetic Nephropathy: A Meta-analysis
por: Deng, Xiaojuan, et al.
Publicado: (2022)

Pentoxifylline plus ACEIs/ARBs for proteinuria and kidney function in chronic kidney disease: a meta-analysis
por: Liu, Dong, et al.
Publicado: (2017)

SARS-CoV-2 downregulation of ACE2 and pleiotropic effects of ACEIs/ARBs
por: Ciulla, Michele M.
Publicado: (2020)

Pharmacological rationale for antihypertensive drug choice on COVID‐19–affected patients: ACEI/ARB might not increase their susceptibility
por: Zhao, Hong‐Jin, et al.
Publicado: (2020)

Effects of ACEI/ARB or CCB use on atrial fibrillation in hypertensive patients following permanent pacemaker implantation
por: Liu, Zhijie, et al.
Publicado: (2023)

Text mining online disinformation about antihypertensive agents ACEI/ARB and COVID-19 on Sina Weibo
por: Wang, Chunli, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_adpojn90pr5u0oc2j8i956c1e3